Is Abivax SA halal to invest in?

According to Musaffa's Shariah screening methodology, Abivax SA (ABVX.PA) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Abivax SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Abivax SA using these criteria to determine its compliance status.

Can Muslims buy shares of Abivax SA?

Muslim investors may consider investing in Abivax SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Abivax SA classified as NOT HALAL?

Musaffa determines the Shariah status of Abivax SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Abivax SA updated?

The Shariah compliance status of Abivax SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Abivax SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Abivax SA?

You can check the latest Shariah compliance status of Abivax SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Abivax SA ABVX.PA

€100.50 €2.20 (2.14%) 1D

Last Updated: May 15, 12:00 AM·XPAR

ABVX.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 05, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Abivax SA (ABVX.PA)

Based on 14 analysts giving stock ratings to Abivax SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Abivax SA. Stock Analysis ABVX.PA

France Health Care Mid Cap Report: 2025 Annual

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Key Statistics of Abivax SA (ABVX.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€99.05€103.90

Today's Open

€102.70

Volume

64.84K

P/E Ratio (TTM)

52 Week Range

€5.00€132.00

Market Cap

7.94B

Avg. Volume

83.04K

Dividend Yield

Financial Metrics & Statements of Abivax SA (ABVX.PA)

FAQ's for Abivax SA (ABVX.PA)

According to Musaffa’s Shariah screening methodology, Abivax SA (ABVX.PA) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.